NVCT
Price:
$13.82
Market Cap:
$366.58M
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Industry
Biotechnology
IPO Date
2022-02-04
Stock Exchange
NASDAQ
Ticker
NVCT
According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -10.55. This represents a change of 82.16% compared to the average of -5.79 of the last 4 quarters.
The mean historical PE Ratio of Nuvectis Pharma, Inc. over the last ten years is -681.15. The current -10.55 PE Ratio has changed 54.89% with respect to the historical average. Over the past ten years (40 quarters), NVCT's PE Ratio was at its highest in in the June 2021 quarter at -1.73. The PE Ratio was at its lowest in in the March 2021 quarter at -451.39.
Average
-681.15
Median
-5.34
Minimum
-4062.50
Maximum
-2.98
Discovering the peaks and valleys of Nuvectis Pharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 66.58%
Maximum Annual PE Ratio = -2.98
Minimum Annual Increase = -99.93%
Minimum Annual PE Ratio = -4062.50
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -5.72 | 17.35% |
| 2024 | -4.87 | -16.43% |
| 2023 | -5.83 | 17.42% |
| 2022 | -4.97 | 66.58% |
| 2021 | -2.98 | -99.93% |
The current PE Ratio of Nuvectis Pharma, Inc. (NVCT) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.48
5-year avg
-4.87
10-year avg
-681.15
Nuvectis Pharma, Inc.’s PE Ratio is less than Innate Pharma S.A. (-2.92), less than Compugen Ltd. (5.48), less than Milestone Pharmaceuticals Inc. (-1.91), less than Tonix Pharmaceuticals Holding Corp. (-0.82), less than Cybin Inc. (-1.57), less than Rani Therapeutics Holdings, Inc. (-1.91), less than Cardiff Oncology, Inc. (-1.81), less than Armata Pharmaceuticals, Inc. (-0.91), less than Molecular Partners AG (-1.98), less than Cassava Sciences, Inc. (-0.76),
| Company | PE Ratio | Market cap |
|---|---|---|
| -2.92 | $169.96M | |
| 5.48 | $190.05M | |
| -1.91 | $111.66M | |
| -0.82 | $191.45M | |
| -1.57 | $413.02M | |
| -1.91 | $51.11M | |
| -1.81 | $82.73M | |
| -0.91 | $259.91M | |
| -1.98 | $143.29M | |
| -0.76 | $63.77M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Nuvectis Pharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Nuvectis Pharma, Inc. (NVCT)?
What is the highest PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 3-year average PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
What is the 5-year average PE Ratio for Nuvectis Pharma, Inc. (NVCT)?
How does the current PE Ratio for Nuvectis Pharma, Inc. (NVCT) compare to its historical average?